，149:1359. 7.Heifets LB， Lindholm-Levy PF， Iseman MD. Rifambutin: minimal inhibitory and bactericidal concentrations for Mycobaterrium tuberculosis. Am Rev Respir dis， 1988， 137:719-721.
8.Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid，streptomycin and rifampicin. Tuber Lung Dis， 1992，73:59.
9.纲谷良一. 新抗结核新药の检讨—新リフアマイシソ诱道体について.结核，1992，67：682.
10.Reddy MV，Luna-Herrera J，Daneluzzi D， et al. Chemotherapeutic activity of benzoxazinorifamycin， KRM-1648， against Mycobacterium tuberculosis in c57BL/6 mice. Tuber Lung Dis, 1996，77: 154-159.
11.Arioli V， Berti M， Carniti G， et al. Antibacterial activity of DL473， a new semisynthetic Rifamycin derivative. J Antikiotics, 1981，34: 1026.
12.何国钧，夏祥新，黄芝芳，等.利福喷丁对初治肺结核的临床研究和三年随访报告.中华结核和呼吸杂志，1993，16：73-76.
13.Tsukamura M. In vitro antituberculosis activity of a new antibacteral substance ofloxacin (DL-8280). Am Rev Respir Dis， 1985，131:348-351.
14.Mor N， Vanderkolk J， Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophage. Antimicrob Agents Chemother，1994，38:1161-1164.
15.Rastogi N， Goh KS， Bryskier A， et al. In vitro activities of levofloxacin used alone and in combination with first and second-line antituberculous drugs against Mycobacteri
un tuberculosis. Antimicrob Agents chemother， 1996，40:1610-1616. 16.Ji B， Lounis N， Maslo C， et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob agents Chemother，1998，42:2066-2069.
17.Crowle AJ， Elkins N， May MH. Effectiveness of ofloxacin against M. tuberculosis and M. Avium， and rifapin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis， 1990， 137:1141-1146.
18.Mitchiso
上一页 [1] [2] [3] [4] [5] [6] [7] [8] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文